Zacks Research Upgrades Electra Therapeutics (NASDAQ:ETRA) to Hold

Electra Therapeutics (NASDAQ:ETRA) was upgraded by Zacks Research to a “hold” rating in a report issued on Wednesday, Zacks reports.

Other equities analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. TD Cowen started coverage on shares of Electra Therapeutics in a report on Tuesday. They issued a “buy” rating for the company. Jefferies Financial Group started coverage on Electra Therapeutics in a research report on Tuesday. They set a “buy” rating and a $32.00 target price for the company. Evercore began coverage on shares of Electra Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 price target for the company. Finally, Cantor Fitzgerald started coverage on Electra Therapeutics in a research note on Tuesday. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Electra Therapeutics has an average rating of “Buy” and a consensus price target of $34.00.

Electra Therapeutics Stock Performance

Electra Therapeutics stock opened at $8.75 on Wednesday. Electra Therapeutics has a fifty-two week low of $8.50 and a fifty-two week high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In other news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were purchased at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the transaction, the director owned 5,126,891 shares of the company’s stock, valued at approximately $76,903,365. This trade represents a 35.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Carl L. Gordon acquired 1,333,333 shares of Electra Therapeutics stock in a transaction dated Monday, September 21st. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the purchase, the director owned 5,126,891 shares in the company, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. The disclosure for this purchase is available in the SEC filing.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.